More specifically, the correlation between serological and biochemical parameters, like CA19-9 and serum amylase, and S100A16 in pancreatic cancer, may be one of our next research directions, which requires further data verification through the collection of a large number of clinical samples from PDAC patients. The gene discussed is S100A16; the disease is pancreatic neoplasm.